Sanara MedTech is an asymmetric surgical medtech turnaround: elite 93% gross margins, accelerating hospital adoption, and major 2027 pipeline optionality offset by high-cost debt and execution risk.
Overview
Sanara MedTech has transformed into a high-growth, pure-play surgical medtech company after exiting its underperforming Tissue Health Plus segment. Its core products—CellerateRX, BIASURGE, and pipeline asset OsStic—target surgical wound healing, antimicrobial irrigation, and bone fixation. The business benefits from exceptional clinical utility, documented hospital savings, recurring consumable usage, and insulation from outpatient reimbursement volatility through inpatient DRG bundling. With strong U.S. hospital access and rapid revenue growth, Sanara is positioned as a specialized challenger in a large surgical wound-care market.